O Shaughnessy Asset Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN

O Shaughnessy Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.2% in the 4th quarter, HoldingsChannel reports. The fund owned 10,495 shares of the biopharmaceutical company’s stock after buying an additional 3,506 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $8,101,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of REGN. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at about $226,000. Arrowstreet Capital Limited Partnership purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at about $3,183,000. Gabelli Funds LLC boosted its holdings in Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 55 shares during the period. Finally, Sei Investments Co. boosted its holdings in Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after acquiring an additional 5,120 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on REGN shares. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Guggenheim upped their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $792.65.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron-backed Parabilis Medicines completed a record-setting biotech IPO, pricing above the expected range and raising about $670 million, plus roughly $75 million from a concurrent private placement to Regeneron. The successful debut suggests strong demand for the asset Regeneron helped finance, which can be viewed as a validation of Regeneron’s deal-making and capital allocation. Article Title
• Positive Sentiment: Regeneron also highlighted progress in its pipeline, with a new clinical study testing weekly Praluent dosing in cholesterol treatment. Any meaningful improvement in dosing convenience or efficacy could support longer-term product growth if the study produces favorable results. Article Title
• Neutral Sentiment: Parabilis’ IPO demand was reported to be exceptionally strong, with pricing above the initial range and shares surging on debut. This is mostly an external event, but it reflects favorably on Regeneron’s strategic backing of the company. Article Title
• Neutral Sentiment: Separately, Regeneron has been mentioned in recent articles about WHO support for an antibody therapy in Ebola-related research. While scientifically encouraging, the near-term market impact appears limited unless it translates into trial progress or commercialization. Article Title
• Negative Sentiment: Law-firm investigation headlines tied to Regeneron are likely pressuring the stock, as fraud/investigation notices can raise concerns about litigation risk and distract from the company’s fundamentals. Similar alerts from Pomerantz and Schall are adding to that overhang. Article Title

Regeneron Pharmaceuticals Stock Down 2.4%

Shares of NASDAQ:REGN opened at $601.65 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $503.25 and a 52-week high of $821.11. The firm has a market capitalization of $63.61 billion, a P/E ratio of 14.66, a P/E/G ratio of 1.35 and a beta of 0.25. The stock has a 50 day moving average price of $698.64 and a 200-day moving average price of $740.06. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the company earned $8.22 EPS. The business’s revenue was up 19.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.